

**ABSTRACT OF THE DISCLOSURE**

Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having  
5 improved bioavailability, and methods of using these compositions for inhibiting the  
replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection.  
These compositions include co-solvent systems, lipid based systems , solid dispersions  
and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one  
pharmaceutically acceptable amine and optionally one or more additional ingredients.

10

15

20

25